Trial intelligence / Profile preview

Continuous infusion antibiotics: serum and epithelial lining fluid concentrations

2005-002128-32Phase 4Completed

Sponsor: Abteilung fÃ¼r Anaesthesiologie und Intensivmedizin
Start: Nov 2005
Modality: Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
Countries: 1

Overview

Phase 4, open-label, single-arm trial of ceftazidime, cefepime, meropenem, piperacillin, tazobactam and 2 more in Infectious disease, sponsored by Abteilung fÃ¼r Anaesthesiologie und Intensivmedizin. Primary endpoints: Serum antibiotic concentration and Antibiotic concentration in epithelial lining fluid. Started Nov 2005; status: completed.

Drugs

ceftazidimecefepimemeropenempiperacillintazobactam

Conditions

Infectious disease

Beyond the preview

Go deeper on 2005-002128-32.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2005-002128-32.